Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 18/20 | 0.39 |
| ▸ | MMP2 | P08253 | 10/20 | 0.38 |
| ▸ | MMP14 | P50281 | 5/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555506 | 1.00 | ADAMTS5 (0.39) | ADAMTS5MMP2MMP14CCR1MMP13 | |
| SCHEMBL1587015 | 1.00 | ADAMTS5 (0.39) | ADAMTS5MMP2MMP14CCR1MMP13 | |
| SCHEMBL14958919 | 0.92 | ADAMTS5 (0.41) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL14958918 | 0.92 | ADAMTS5 (0.41) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL1555020 | 0.88 | ADAMTS5 (0.45) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL1556341 | 0.88 | ADAMTS5 (0.45) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL1555993 | 0.88 | ADAMTS5 (0.45) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL1586945 | 0.88 | ADAMTS5 (0.45) | ADAMTS5MMP2MMP14MMP13ADAM17 | |
| SCHEMBL734823 | 0.88 | LIPE (0.34) | ADAMTS5MMP2MMP14CCR1ADAMTS4 | |
| SCHEMBL734822 | 0.88 | LIPE (0.34) | ADAMTS5MMP2MMP14CCR1ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2491022-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048032-A1 | DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR1 | ADAMTS5 4275/4885MMP2 3397/4885MMP14 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.